David M. Briere

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS ^G12D Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 708 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 594 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 507 citations

Medicine, Medicinal Chemistry, Oncology +9

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters et al. · Cancer Discovery · 2023 · 194 citations · Full text

Medicine, Oncology, Pharmacology +10